186 related articles for article (PubMed ID: 1960751)
21. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
23. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Jones SE; Khandelwal P; McIntyre K; Mennel R; Orr D; Kirby R; Agura E; Duncan L; Hyman W; Roque T; Regan D; Schuster M; Dimitrov N; Garrison L; Lange M
J Clin Oncol; 1999 Oct; 17(10):3025-32. PubMed ID: 10506596
[TBL] [Abstract][Full Text] [Related]
24. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
Havemann K; Klausmann M; Wolf M; Fischer JR; Drings P; Oster W
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493
[TBL] [Abstract][Full Text] [Related]
25. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
[TBL] [Abstract][Full Text] [Related]
26. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
Gill PS; Bernstein-Singer M; Espina BM; Rarick M; Magy F; Montgomery T; Berry MS; Levine A
AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520
[TBL] [Abstract][Full Text] [Related]
27. [The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma].
Biesma B; Willemse PH; Vellenga E; Limburg PC; Aalders JG; de Vries EG
Ned Tijdschr Geneeskd; 1991 Mar; 135(10):420-4. PubMed ID: 2020314
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
29. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
O'Shaughnessy JA; Tolcher A; Riseberg D; Venzon D; Zujewski J; Noone M; Gossard M; Danforth D; Jacobson J; Chang V; Goldspiel B; Keegan P; Giusti R; Cowan KH
Blood; 1996 Mar; 87(6):2205-11. PubMed ID: 8630380
[TBL] [Abstract][Full Text] [Related]
30. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
[TBL] [Abstract][Full Text] [Related]
31. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
Herrmann F; Schulz G; Wieser M; Kolbe K; Nicolay U; Noack M; Lindemann A; Mertelsmann R
Am J Med; 1990 Jun; 88(6):619-24. PubMed ID: 2189305
[TBL] [Abstract][Full Text] [Related]
32. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.
Stöger H; Samonigg H; Krainer M; Ploszczynski M; Nirnberger G; Maca S; Hehenwarter W; Wirth M; Schüller J; Vavra N; Scheithauer W; Kornek G; Stierer M; Zielinski CC
Eur J Cancer; 1998 Mar; 34(4):482-8. PubMed ID: 9713297
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer.
Kobrinsky NL; Sjolander DE; Cheang MS; Levitt R; Steen PD
J Clin Oncol; 1999 Nov; 17(11):3426-30. PubMed ID: 10550137
[TBL] [Abstract][Full Text] [Related]
34. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
Osborne CK; Sunderland MC; Neidhart JA; Ravdin PM; Abeloff MD
Ann Oncol; 1994 Jan; 5(1):43-7. PubMed ID: 8172792
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
Bokemeyer C; Schmoll HJ; Metzner B; Beyer J; Illiger HJ; Kneba M; Ostermann H; Kynast B; Räth U; Poliwoda H
Ann Hematol; 1993 Aug; 67(2):75-9. PubMed ID: 8347733
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
37. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
[TBL] [Abstract][Full Text] [Related]
38. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
[TBL] [Abstract][Full Text] [Related]
39. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
Honkoop AH; Hoekman K; Wagstaff J; van Groeningen CJ; Vermorken JB; Boven E; Pinedo HM
Br J Cancer; 1996 Oct; 74(7):1132-6. PubMed ID: 8855987
[TBL] [Abstract][Full Text] [Related]
40. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
